Development of new pyrrolopyrimidine-based inhibitors of Janus kinase 3 (JAK3).
A new class of bicyclic pyrrolopyrimidine-based Janus kinase 3 (JAK-3) inhibitors are described. Many of these inhibitors showed low nanomolar activity against JAK-3.
Clark
Michael P
MP
Procter and Gamble Pharmaceuticals, Health Care Research Center, 8700 Mason-Montgomery Road, Mason, OH 45040, USA. mclark@metastatix.com
George
Kelly M
KM
Bookland
Roger G
RG
Chen
Jack
J
Laughlin
Steven K
SK
Thakur
Kumar D
KD
Lee
Wenlin
W
Davis
Jan R
JR
Cabrera
Ed J
EJ
Brugel
Todd A
TA
VanRens
John C
JC
Laufersweiler
Matthew J
MJ
Maier
Jennifer A
JA
Sabat
Mark P
MP
Golebiowski
Adam
A
Easwaran
Vijay
V
Webster
Mark E
ME
De
Biswanath
B
Zhang
George
G
D001327:Autoimmune Diseases / Q000188:drug therapy; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D006801:Humans; D007109:Immunity / Q000187:drug effects; D053614:Janus Kinase 2 / Q000037:antagonists & inhibitors; D053616:Janus Kinase 3 / Q000037:antagonists & inhibitors*; D011743:Pyrimidines / Q000138:chemical synthesis* / Q000494:pharmacology; D011758:Pyrroles / Q000138:chemical synthesis* / Q000494:pharmacology; D013329:Structure-Activity Relationship
D011743:Pyrimidines; D011758:Pyrroles; D053614:Janus Kinase 2; D053616:Janus Kinase 3